15th Feb 2007 07:01
Immupharma PLC15 February 2007 For Immediate Release 15 February 2007 ImmuPharma plc Appointment of adviser ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drugdiscovery and development company ImmuPharma plc is pleased to announce theappointment of Teather & Greenwood Limited as nominated adviser and broker. Theappointment is with immediate effect. Dawnay, Day Corporate Finance Limited continues to act for ImmuPharma plc asjoint financial adviser. For further information please contact: ImmuPharma PLC:Richard Warr, Chairman + 44 20 7152 4080Dimitri Dimitriou, Chief ExecutiveOfficer Buchanan Communications + 44 20 7466 5000Lisa Baderoon / Rebecca SkyeDietrich Notes to Editors:About ImmuPharma ImmuPharma PLC is a drug discovery and development company headquartered inLondon, UK and quoted on AIM of the London Stock Exchange (LSE:IMM). It hasresearch operations in France (ImmuPharma (France) SA) and Switzerland(ImmuPharma AG). ImmuPharma is dedicated to the development of novel drugs,largely based on peptide therapeutics, to treat serious medical conditions suchas autoimmune diseases characterised by: * blockbuster potential in niche markets * low promotional costs in few specialised physicians and centres and * lower risk of drug development and lower development costs ImmuPharma is a currently developing drug candidates for three different medicalconditions, each of which would represent a significant breakthrough in itsfield. The furthest advanced drug candidate targets Lupus, a disease for whichthere is currently no cure or specific treatment. The other two address moderateto severe pain (such as that experienced by cancer sufferers and post-operativepatients), and MRSA and similar severe hospital-acquired resistant infections. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Immupharma